Isomorphic Labs融資21億美元用於AI藥物發現
alphabet旗下的isomorphic labs在thrive capital領投的b輪融資中籌集了21億美元，以推動ai生成的藥物候選物進入臨床試驗。
alphabet subsidiary isomorphic labs secured $2.1 billion in series b funding co-led by thrive capital to scale its ai-driven drug discovery platform. the capital injection aims to advance the company's pipeline of therapeutics into clinical trials and support global hiring efforts for its isodde ai system. founder demis hassabis stated the technology has proven itself and focuses on the mission to solve all disease. this funding reinforces the viability of ai in biotech, bolstering existing collaborations with major pharmaceutical firms like novartis, lilly, and johnson & johnson.